ライフサイエンスコーパス: solid organ

1 , 1519 (14.0%) hematologic, and 4842 (44.7%) solid organ.

2 thin the centre of an initially unpolarised, solid organ.

3 bring us closer to the promise of engineered solid organs.

4 ater than those of the commonly transplanted solid organs.

5 port cells surrounding microvessels found in solid organs.

6 se that was already established in secondary solid organs.

7 e myriad of approaches attempted to engineer solid organs, 3D bioprinting offers unmatched potential.

8 RI) and antibody-mediated rejection (AMR) of solid organ allografts.

9 on continues to hinder long-term survival of solid organ allografts.

10 splant recipients of concomitantly recovered solid organ allografts.

11 V) infection remains a major complication in solid organ and hematopoietic cell transplant recipients

12 -mediated lymphoablation is commonly used in solid organ and hematopoietic cell transplantation.

13 gy of significant morbidity and mortality in solid organ and hematopoietic stem cell transplant recip

14 eightened risk for infection associated with solid organ and hematopoietic stem cell transplantation,

15 ection and graft-versus-host disease in both solid organ and hematopoietic stem cell transplantation.

16 nd therapeutic challenges in neutropenia and solid organ and hematopoietic stem cell transplantation.

17 m was to assess the risk for MS in pediatric solid organ and stem cell transplant recipients by compa

18 term outcomes of the concomitantly recovered solid organs and their recipients.

19 of the key unmet needs in the fields of both solid-organ and hematopoietic stem cell transplant (HCT)

20 ts, in vitro formation of a fully functional solid organ at a translatable scale has not yet been ach

21 alysis of the family overrule of donation of solid organs by deceased patients, and examine arguments

22 ed risk of posttransplant skin cancer, PTLD, solid organ cancer, death and graft failure.

23 years preceding diagnosis and treatment; for solid organ cancers, the increased risk appears to be la

24 ) developed 73 nonskin cancers, including 46 solid-organ cancers (renal, 11; colorectal, 11; prostate

25 ry T (T reg) cells in opposing and promoting solid organ carcinogenesis, respectively, is viewed as a

26 The number of patients suffering from solid organ disease continues to increase, with over 100

27 ospectively identified all successful US DCD solid organ donors from 1/2011 to 3/1/2017, defined an i

28 on Network database from 2000 to 2012 of all solid organ donors.

29 d data on the nonprocurement of kidneys from solid organ donors.

30 ansplanting young adults and the shortage of solid organs for transplant, future studies are critical

31 The availability of solid organs for transplantation remains low and there i

32 s, one major goal is to bioengineer complex, solid organs for transplantation, composed of patient-sp

33 fied the population of subjects who received solid organs from these 10 donors using the Scientific R

34 s that mesenchymal stromal cells can prolong solid organ graft survival and that they can induce immu

35 te and long-term persistence of transplanted solid organs has become increasingly evident in recent y

36 Regions-of-interest were drawn in multiple solid organs including the pancreas and T(1) and T(2) va

37 ore regulators of fibroblast activity across solid organs, including the kidneys.

38 There were 17 unidentified solid organ injuries, and eight patients had active blee

39 rience on the transplantation of HCV-viremic solid organs into recipients who are HCV negative.

40 Antibody-mediated rejection (AMR) of most solid organs is characterized by evidence of complement

41 tion outcomes of the concomitantly recovered solid organs is limited to isolated case reports and sho

42 ty from cirrhosis, hepatocellular carcinoma, solid organ malignancies, diabetes mellitus, cardiovascu

43 ing has become the standard for staging most solid organ malignancies.

44 findings are combined with the presence of a solid organ mass, lymphoma should be included in the dif

45 compromised patients who are recipients of a solid organ or hematopoietic stem cell transplant are li

46 y bowel disease, dermatologic conditions, or solid-organ or bone marrow transplantation.

47 biophysical properties and forces to shape a solid organ primordium.

48 Thus, confronted with infection in solid organ recipients, the management of immunosuppress

49 sion and could lead to improved outcomes for solid organ recipients.

50 donors in the United States with at least 1 solid organ recovered.

51 allows sequestration of a kidney by another solid organ regardless of the priority of the candidate

52 The Kidney Solid Organ Response Test (kSORT) blood gene expression

53 blood biomarkers, the transcriptional kidney Solid Organ Response Test (kSORT), and the IFN-gamma enz

54 ansplantation of hematopoietic cell (HCT) or solid organ (SOT) but is unavailable for most patients.M

55 allenges remain when addressing more complex solid organs such as the heart, liver, and kidney.

56 VCA donors also donated solid organs that were transplanted, including 87.1% of

57 ayo Clinic who had bone marrow, fat pad, and solid organ tissue samples typed by liquid chromatograph

58 e achieved with the transition of engineered solid organs to the clinic.

59 next-generation HSCT-mediated therapies for solid organ tolerance, cure of non-malignant hematologic

60 use for transplantation is the lowest among solid organ tranplants because of several complex and mu

61 of patients, including HIV infection (45%), solid organ transplant (26%), and cirrhosis (22%).

62 Data describing antibiotic allergies among solid organ transplant (SOT) and hematopoietic cell tran

63 ous diseases physicians in persons receiving solid organ transplant (SOT) between May 2008 and Decemb

64 for exercise training in adult and children solid organ transplant (SOT) candidates and recipients a

65 Solid organ transplant (SOT) candidates and recipients a

66 In this cross-sectional study of solid organ transplant (SOT) candidates and recipients,

67 cal and molecular pretransplant screening in solid organ transplant (SOT) donors and recipients in no

68 Two groups were identified: the solid organ transplant (SOT) group (n = 15; 12 ITX and 3

69 ally ill coronavirus disease 2019 (COVID-19) solid organ transplant (SOT) patients are limited.

70 Despite annual immunization, solid organ transplant (SOT) patients remain at increase

71 responses to natural influenza infection in solid organ transplant (SOT) patients.

72 Solid organ transplant (SOT) recipients are at elevated

73 Hematopoietic cell transplant (HCT) and solid organ transplant (SOT) recipients are at increased

74 Solid organ transplant (SOT) recipients are at risk of n

75 tis jirovecii pneumonia (PJP) prophylaxis in solid organ transplant (SOT) recipients at increased ris

76 ause severe infections in seronegative adult solid organ transplant (SOT) recipients but can be preve

77 Solid organ transplant (SOT) recipients comprise a large

78 In fall 2017, 3 solid organ transplant (SOT) recipients from a common do

79 , and immune responses in HIV-infected adult solid organ transplant (SOT) recipients on antiretrovira

80 ological response (SVR) in a large cohort of solid organ transplant (SOT) recipients with chronic HEV

81 enteritis can cause intractable diarrhea in solid organ transplant (SOT) recipients, for which there

82 D-19 among immunosuppressed patients such as solid organ transplant (SOT) recipients, who are at pres

83 own about COVID-19, including its effects on solid organ transplant (SOT) recipients.

84 a major cause of morbidity and mortality in solid organ transplant (SOT) recipients.

85 failure in adolescent and young adult (AYA) solid organ transplant (SOT) recipients.

86 s associated with morbidity and mortality in solid organ transplant (SOT) recipients.

87 CMV) is an emerging and important problem in solid organ transplant (SOT) recipients.

88 disproportionately more severe disease among solid organ transplant (SOT) recipients.

89 cer, human immunodeficiency virus (HIV), and solid organ transplant (SOT).

90 ad immunosuppression (120; 82.8%), including solid organ transplant (SOT; 33.8%), autoimmunity (15.9%

91 ncer (hematologic and solid tumor), HIV, and solid organ transplant (SOT; kidney and other).

92 Patients listed or being evaluated for solid organ transplant after January 26, 2018, were educ

93 l infarction, stroke, hemorrhagic shock, and solid organ transplant are particularly prone to cause I

94 repository, in parallel with systems used by solid organ transplant centers.

95 ant recipients that in turn has impacted the solid organ transplant community as well.

96 umoral rejection is the most common cause of solid organ transplant failure.

97 inimization and avoidance protocols for post-solid organ transplant have been developed.

98 Receiving a solid organ transplant owing to late-stage organ failure

99 Solid organ transplant patients with first episode of CM

100 (Carbapenem-Resistant Enterobacteriaceae in Solid Organ Transplant Patients) has provided pivotal da

101 In solid organ transplant patients, global suppression of i

102 emerged as a cause of persistent diarrhea in solid organ transplant patients.

103 romised individuals, such as bone marrow and solid organ transplant patients.

104 We reported 47 solid organ transplant recipients (41 kidneys) with cryp

105 reported an increased risk of skin cancer in solid organ transplant recipients (OTRs), no study has e

106 De novo solid organ transplant recipients (SOTR) have a steep le

107 Solid organ transplant recipients (SOTR) with a pretrans

108 Solid organ transplant recipients (SOTr) with coronaviru

109 The number of solid organ transplant recipients (SOTR), and their life

110 is a significant opportunistic infection in solid organ transplant recipients (SOTR).

111 enza vaccine effectiveness is not optimal in solid organ transplant recipients (SOTR).

112 or contributor to morbidity and mortality in solid organ transplant recipients (SOTRs).

113 iabetes mellitus (PTDM) affects up to 50% of solid organ transplant recipients and compromises long-t

114 Diabetes is prevalent among solid organ transplant recipients and is universal among

115 Solid organ transplant recipients are at increased risk

116 Solid organ transplant recipients are at risk for potent

117 as treatment of chronic hepatitis C virus in solid organ transplant recipients are limited.

118 VZV immunization of pediatric solid organ transplant recipients confers sustained sero

119 -scale retrospective study that included 255 solid organ transplant recipients confirms that ribaviri

120 Pediatric solid organ transplant recipients demonstrate worse over

121 testing novel immunotherapy combinations in solid organ transplant recipients designed to uncouple a

122 Solid organ transplant recipients have an increased risk

123 Solid organ transplant recipients have increased risk fo

124 ntions to prevent nonmelanoma skin cancer in solid organ transplant recipients have not been summariz

125 We report four cases of COVID-19 in solid organ transplant recipients including recipients o

126 atforms to support the postoperative care of solid organ transplant recipients is evolving.

127 Currently, 1 in 6 pediatric solid organ transplant recipients is hospitalized with a

128 Solid organ transplant recipients may be at a high risk

129 n-resistant Enterococcus faecium (LR-VRE) in solid organ transplant recipients remain uncommon, they

130 ng Enterobacteriaceae and CRE carriage among solid organ transplant recipients to inform management o

131 cancer was assessed among 118,440 Caucasian solid organ transplant recipients using multivariate Cox

132 The impact of these therapies in solid organ transplant recipients was not assessed in cl

133 omes associated with low PA in adult single, solid organ transplant recipients were included.

134 high-throughput gene expression datasets of solid organ transplant recipients were retrieved from th

135 Approximately 33.6% of nondiabetic solid organ transplant recipients who received tacrolimu

136 andemic of SARS-CoV-2, there is concern that solid organ transplant recipients will be particularly v

137 In contrast, reports of solid organ transplant recipients with clinical features

138 ms, clinical severity, and disease course in solid organ transplant recipients with COVID-19, includi

139 We herein report our initial experience with solid organ transplant recipients with SARS-CoV-2 infect

140 ears to be safe and immunogenic in pediatric solid organ transplant recipients, but there are few dat

141 er phase II trial, 152 treatment-naive adult solid organ transplant recipients, with CD20(+) PTLD unr

142 vity (PA) and its correlates and outcomes in solid organ transplant recipients.

143 both the hematology-oncology population and solid organ transplant recipients.

144 ts to prevent nonmelanoma skin cancers among solid organ transplant recipients.

145 andomized trials of eHealth interventions in solid organ transplant recipients.

146 l-based adjunct immunosuppressive therapy in solid organ transplant recipients.

147 ing the incidence of rejection in HIV-to-HIV solid organ transplant recipients.

148 y of cases of antibody-mediated rejection in solid organ transplant recipients.

149 stemic non-Hodgkin lymphoma (NHL) in 288 029 solid organ transplant recipients.

150 on growth and safety parameters in pediatric solid organ transplant recipients.

151 ell recognized but uncommon complications in solid organ transplant recipients.

152 nd a leading cause of cancer mortality among solid organ transplant recipients.

153 interventions to support self-management in solid organ transplant recipients.

154 OVID-19 has the potential to severely impact solid organ transplant recipients.

155 hoproliferative disease (PTLD) arising after solid organ transplant remains contentious.

156 -pollination and synergy between corneal and solid organ transplant research communities.

157 economics willingness-to-pay threshold to a solid organ transplant setting by coining a new metric:

158 e to ten-fold risk (25 to 30 fold risk after solid organ transplant) of colorectal cancer (CRC) than

159 tion of C. difficile in hematology-oncology, solid organ transplant, and HIV-infected patients.

160 been used to treat chronic HEV infection in solid-organ transplant patients with some success.

161 Hematopoietic-cell or solid-organ transplant recipients >=12 years old with RR

162 and risk factors of obesity among pediatric solid-organ transplant recipients (heart, lung, liver, k

163 and risk factors of obesity among pediatric solid-organ transplant recipients (heart, lung, liver, k

164 0 fresh CMV DNA-positive plasma samples from solid-organ transplant recipients (SOTRs) were tested.

165 ical trials with expanded T(regs) in T1D and solid-organ transplant recipients are limited by poor T(

166 sed for cytomegalovirus (CMV) prophylaxis in solid-organ transplant recipients.

167 immunocompromised individuals, especially in solid-organ transplant recipients.

168 dergoing nonurologic surgeries, and nonrenal solid-organ transplant recipients.

169 drug-resistant/recurrent cytomegalovirus in solid-organ transplant recipients.METHODSIn the present

170 Suppression of solid-organ transplant rejection has traditionally focus

171 gs) in both murine and human recipients of a solid-organ transplant.

172 nd 2018 with a diagnosis of amyloidosis post solid-organ transplant.

173 is the first description of amyloidosis post solid-organ transplant; 30 cases among 5112 amyloid pati

174 OR, 3.12), radiation therapy (OR, 5.28), and solid organ transplantation (OR, 2.48) increased the ris

175 ls effectively excluding patients with prior solid organ transplantation (SOT) and posttransplant lym

176 xis effectively prevents CMV infection after solid organ transplantation (SOT) but is associated with

177 Patients undergoing evaluation for solid organ transplantation (SOT) frequently have a hist

178 e infection (CDI) treatment; however, use in solid organ transplantation (SOT) patients has theoretic

179 Information on solid organ transplantation (SOT) performed in pediatric

180 late severe infection (LI) beyond month 6 in solid organ transplantation (SOT) recipients.

181 sequently, evidence-based recommendations in solid organ transplantation (SOT) remain challenging and

182 rol of cytomegalovirus (CMV) infection after solid organ transplantation (SOT) requires a functional

183 iasm as an innovative cell-based approach in solid organ transplantation (SOT).

184 receptors, in regulating the alloresponse to solid organ transplantation (SOT).

185 tration on a waiting list for or receiving a solid organ transplantation and 5-year survival followin

186 ause of a complex diagnosis especially after solid organ transplantation and can lead to difficulties

187 ociated with rejection and allograft loss in solid organ transplantation and may act synergistically

188 g the periocular region represents a risk of solid organ transplantation and may produce significant

189 mpatibility between patient and donor before solid organ transplantation and preventing hyperacute re

190 The largest reductions in solid organ transplantation and waitlist deaths were see

191 epts for antibody reduction before and after solid organ transplantation are considered, to better un

192 ions for use of the latter in the setting of solid organ transplantation are presented in the accompa

193 tween Jan 1, 1970, and Dec 31, 1986 (without solid organ transplantation before cohort entry) to the

194 Outcomes after solid organ transplantation continue to improve, but pre

195 However, the number of patients awaiting solid organ transplantation continues to remain much hig

196 Solid organ transplantation disrupts virus-host relation

197 9 (COVID-19) pandemic to continue lifesaving solid organ transplantation for heart, lung, liver, and

198 ven patients who were HCV negative underwent solid organ transplantation from a donor who was HCV vir

199 Solid organ transplantation from hepatitis C virus-posit

200 Allergy transfer upon solid organ transplantation has been reported in the lit

201 of the oral cavity, which may develop after solid organ transplantation in children.

202 gional impact of coronavirus disease 2019 on solid organ transplantation in the United States has not

203 fic exposures were associated with increased solid organ transplantation incidence.

204 Solid organ transplantation is a curative therapy for hu

205 Solid organ transplantation is a lifesaving therapy for

206 Tobacco use after solid organ transplantation is associated with allograft

207 Medication nonadherence (MNA) after solid organ transplantation is highly prevalent and asso

208 However, using ID as a contraindication to solid organ transplantation is not evidence-based and re

209 Solid organ transplantation is uncommon in ageing childh

210 Successful solid organ transplantation reflects meticulous attentio

211 nor-specific antibodies, conclusions made in solid organ transplantation regarding antibody-mediated

212 to support self-management, but evidence in solid organ transplantation remains unclear.

213 Survival outcomes showed that solid organ transplantation should be considered for 5-y

214 emphasizing the parallels between women and solid organ transplantation that could allow vaccines to

215 A consensus conference on frailty in solid organ transplantation took place on February 11, 2

216 5-year overall survival after solid organ transplantation was 93.5% (95% CI 81.0-97.9)

217 Many children who have undergone solid organ transplantation will require additional supp

218 clinical research on stem cells, tissues, or solid organ transplantation with >=20 participants, whic

219 rent developments in tolerance induction for solid organ transplantation with a particular emphasis o

220 oviders, offering ideas to improve safety in solid organ transplantation with limited health care res

221 cipients, showing potential applications for solid organ transplantation without immune suppression.

222 cute and chronic rejection in the context of solid organ transplantation, and emerging evidence sugge

223 of childbearing age, toddlers, recipients of solid organ transplantation, and stem cell transplant pa

224 trials, including those for bone marrow and solid organ transplantation, autoimmune diseases, and ti

225 Excessive weight (EW) gain is common after solid organ transplantation, but there is little informa

226 In solid organ transplantation, donor-derived immune cells

227 eing placed on a waiting list or receiving a solid organ transplantation, hazard ratios (HRs) for ide

228 As with solid organ transplantation, however, rejection must be

229 After solid organ transplantation, immune-mediated rejection m

230 ty, are now being translated to the field of solid organ transplantation, particularly for livers and

231 Organ scarcity continues in solid organ transplantation, such that the availability

232 of novel immunosuppressive drugs for use in solid organ transplantation.

233 circulation is an early marker of injury in solid organ transplantation.

234 hing is a risk factor for graft rejection in solid organ transplantation.

235 including stroke, myocardial infarction, and solid organ transplantation.

236 eed for systemic immunosuppression in VCA or solid organ transplantation.

237 ening and vaccination of all patients before solid organ transplantation.

238 ative correlation with long-term survival in solid organ transplantation.

239 nition of being physically active) following solid organ transplantation.

240 ary Epstein-Barr virus (EBV) infection after solid organ transplantation.

241 hematopoietic stem cell transplantation and solid organ transplantation.

242 he development of immunoregulation following solid organ transplantation.

243 Diarrhea is a frequent complication of solid organ transplantation.

244 oles in the cellular and humoral response in solid organ transplantation.

245 dressing the organ supply/demand mismatch in solid organ transplantation.

246 cluding those associated with bone marrow or solid organ transplantation.

247 thogenesis of ischemia-reperfusion injury in solid organ transplantation.

248 ications of this novel MPS classification in solid organ transplantation.

249 used to prevent rejection and graft loss in solid organ transplantation.

250 neity of lymphatic vessels in the context of solid organ transplantation.

251 ively ameliorates the consequences of IRI in solid organ transplantation.

252 unosuppression minimization or withdrawal in solid organ transplantation.

253 n diagnosis and personalized therapeutics in solid organ transplantation.

254 s, but also as an unavoidable consequence of solid organ transplantation.

255 define the role of MP therapeutic agents in solid organ transplantation.

256 intravenous drug use, radiation therapy, and solid organ transplantation.

257 respect to safety for recipients undergoing solid-organ transplantation from donors with a history o

258 Development of amyloidosis post solid-organ transplantation has not been reported, altho

259 based cohort study of patients who underwent solid-organ transplantation in Ontario, Canada, between

260 health concern; however, the incidence post solid-organ transplantation is not well reported.

261 promising strategy to induce tolerance after solid-organ transplantation or prevent graft-versus-host

262 The SMR for cancer death after solid-organ transplantation was higher in children (SMR,

263 ars suggests that amyloidosis may occur post solid-organ transplantation with an overall poor surviva

264 deed required in hematopoietic stem cell and solid-organ transplantation, and the histocompatibility

265 allograft loss in most (if not all) types of solid-organ transplantation.

266 Of 13 318 eligible survivors, 100 had 103 solid organ transplantations (50 kidney, 37 heart, nine

267 ms are used to prolong allograft survival in solid organ transplantations and have been shown to be s

268 o not always mimic those of the well-studied solid organ transplantations.

269 ed all cryptosporidiosis cases identified in solid organ transplanted patients between 2006 and 2010

270 ssessed graft survival through 1 year of all solid organs transplanted from 370 donors who had been r

271 Recipients of nonkidney solid organ transplants (nkSOT) are living longer, and 1

272 Patients waitlisted for and recipients of solid organ transplants (SOT) are perceived to have a hi

273 gained over the years shows that, similar to solid organ transplants (SOT), human VCA can also develo

274 s posed by invasive biopsy for monitoring of solid organ transplants (SOTs).

275 plications for sensitized patients receiving solid organ transplants and antibody-mediated rejection

276 We included pediatric recipients of solid organ transplants at the Hospital for Sick Childre

277 equirement for immunosuppression compared to solid organ transplants because of the inherent immune p

278 were seen in recipients receiving noncardiac solid organ transplants from simvastatin-treated donors.

279 on of continuous distribution models for all solid organ transplants may allow for minimization of th

280 inical trials to treat patients with cancer, solid organ transplants, and autoimmune diseases.

281 ations, including patients with neutropenia, solid organ transplants, and nonurologic surgery.

282 the liver less prone to rejection than other solid organ transplants, and reaction to local injury, s

283 ew will discuss key studies in the different solid organ transplants, recent reports of adverse event

284 jection, which is in sharp contrast to other solid organ transplants, such as kidney, lung, and heart

285 ng a significant clinical problem across all solid organ transplants, there are limited therapeutics

286 ts with cancer or recipients of stem cell or solid organ transplants.

287 ansplantation of hematopoietic stem cells or solid organ transplants.

288 ffects on graft survival in several types of solid organ transplants.

289 the major obstacle for long-term survival of solid organ transplants.

290 d trial, recipients of hematopoietic-cell or solid-organ transplants (>=18 years of age, with CMV rea

291 ividuals with inflammatory bowel diseases or solid-organ transplants, virome dynamics in allogeneic h

292 ia among recipients of hematopoietic-cell or solid-organ transplants.

293 Solid organs transport fluids through distinct vascular

294 eath 1 (PD-1) antibodies in the treatment of solid-organ tumors, with an estimated frequency of 4.2%.

295 ID-19 trajectory compared with patients with solid organ tumours (odds ratio [OR] 1.57, 95% CI 1.15-2

296 A total of 36 solid organs were recovered and transplanted into 35 rec

297 We showcase key advances in bioprinting solid organs with complex vascular networks and function

298 planting immunologically mismatched HSCs and solid organs with limited toxicity.

299 bowel lumen, wall, perienteric tissues, and solid organs within the abdomen.

300 enografts that may be applicable to clinical solid organ xenotransplantation.